- Long-term survival on vemurafenib monotherapy2017 | Publication without faculty affiliation
- Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutatuion positive melanoma(BRIM-3): extended follow up of phase 3 randimised open label study2014 | Publication without faculty affiliation
- Pokračování v léčbě vemurafenibem i po progresi onemocnění2016 | Publication without faculty affiliation
- Atypická velmi pomalá regrese metastáz melanomu při léčbě vemurafenibem2016 | First Faculty of Medicine
- Cobimetinib - progress in the treatment of melanoma2017 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Dlouhodobé přežívání pacientky s metastazujícím melanomem při monoterapii vemurafenibem2016 | First Faculty of Medicine
- Malignant melanoma2013 | Third Faculty of Medicine
- Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure2017 | Third Faculty of Medicine
- Research Report University Hospital for clinical assessment GO27826Publication without faculty affiliation
- The Year 2011 is the Year of Melanoma: Melanoma Forum, Frankfurt, 19. May 20112011 | Faculty of Medicine in Hradec Králové
- Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study2019 | Second Faculty of Medicine
- An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system2019 | First Faculty of Medicine
- Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis2017 | Publication without faculty affiliation
- Severe diclofenac photoallergy in a patient treated with vemurafenib2016 | Third Faculty of Medicine
- Nonhealing atopic eczema2017 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study2014 | Publication without faculty affiliation
- Pacient s mnohočetnými kožními metastázami maligního melanomu léčený vemurafenibem - kasuistika2016 | First Faculty of Medicine
- BRAF mutation: a novel approach in targeted melanoma therapy2012 | Third Faculty of Medicine
- Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management2019 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment GO28141Publication without faculty affiliation
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial2018 | First Faculty of Medicine
- Rychlý nástup a dlouhé trvání kompletní remise u pacienta s BRAF V600 pozitivním metastazujícím melanomem léčeným vemurafenibem2016 | First Faculty of Medicine
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial2018 | First Faculty of Medicine
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma2020 | First Faculty of Medicine
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib2015 | Publication without faculty affiliation
- Kudy v léčbě metastatického maligního melanomu2016 | Publication without faculty affiliation
- Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas2017 | Second Faculty of Medicine, Central Library of Charles University
- Dual targeted therapy in patients with malignant melanoma2017 | Faculty of Medicine in Hradec Králové
- New treatment options for malignant melanoma2014 | Faculty of Medicine in Pilsen
- New trends in the multiple myeloma treatment2019 | First Faculty of Medicine